- $79.35m
- $44.71m
- $7.01m
- 25
- 11
- 77
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.2 | ||
| Price to Tang. Book | 2.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -85.62% | ||
| Return on Equity | -84.68% | ||
| Operating Margin | -478% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.48 | 4.5 | 5.17 | 6.21 | 7.01 | 8.86 | 24.11 | 13.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Directors
- Paul Stuka NEC (66)
- Marvin Slosman PRE (57)
- Craig Shore CFO (60)
- Kathryn Arnold IND (49)
- Michael Berman IND (63)
- Thomas Kester IND (73)
- Campbell Rogers IND (60)
- Gary Roubin IND (73)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 29th, 2008
- Public Since
- April 12th, 2013
- No. of Shareholders
- 293
- No. of Employees
- 85
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 30,635,346
- Address
- 4 Menorat Hamaor St., TEL AVIV-YAFO, 6744832
- Web
- https://www.inspiremd.com/en/
- Phone
- +1 8574536553
- Contact
- Craig Shore
- Auditors
- Kesselman & Kesselman
Upcoming Events for NSPR
Q1 2025 InspireMD Inc Earnings Release
InspireMD Inc Annual Shareholders Meeting
InspireMD Inc Annual Shareholders Meeting
Q2 2025 InspireMD Inc Earnings Release
Similar to NSPR
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the InspireMD share price?
As of Today at 21:20 UTC, shares in InspireMD are trading at $2.59. This share price information is delayed by 15 minutes.
How has the InspireMD share price performed this year?
Shares in InspireMD last closed at $2.59 and the price had moved by +35.25% over the past 365 days. In terms of relative price strength the InspireMD share price has outperformed the S&P500 Index by +24.84% over the past year.
What are the analyst and broker recommendations for InspireMD?
The overall consensus recommendation for InspireMD is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the InspireMD dividend yield?
InspireMD does not currently pay a dividend.
Does InspireMD pay a dividend?
InspireMD does not currently pay a dividend.
When does InspireMD next pay dividends?
InspireMD does not currently pay a dividend.
How do I buy InspireMD shares?
To buy shares in InspireMD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of InspireMD?
As of the previous close price of $2.59, shares in InspireMD had a market capitalisation of $79.35m.
Where are InspireMD shares listed?
Here are the trading details for InspireMD:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NSPR
What kind of share is InspireMD?
Based on an overall assessment of its quality, value and momentum InspireMD is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a InspireMD share price forecast for 2025?
The analyst consensus target price for shares in InspireMD is $4.75. That is 83.4% above the last closing price of $2.59.
Analysts covering InspireMD currently have a consensus Earnings Per Share (EPS) forecast of -$0.90 for the next financial year.
Find out moreWhat is the trend in the InspireMD share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like InspireMD. Over the past six months, its share price has outperformed the S&P500 Index by +11.42%.
As of the last closing price of $2.59, shares in InspireMD were trading -5.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the InspireMD PE Ratio?
The InspireMD PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of InspireMD?
InspireMD's management team is headed by:
- Paul Stuka - NEC
- Marvin Slosman - PRE
- Craig Shore - CFO
- Kathryn Arnold - IND
- Michael Berman - IND
- Thomas Kester - IND
- Campbell Rogers - IND
- Gary Roubin - IND